Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 5/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 13/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329659 | 1.00 | ADRB3 (0.76) | ADRB3ADRB2HPGDADRB1 | |
| SCHEMBL6336211 | 0.90 | ADRB3 (0.77) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6336213 | 0.90 | ADRB3 (0.77) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6326153 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6326159 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6334520 | 0.81 | ADRB3 (0.77) | ADRB3ADRB2HPGDADRB1 | |
| SCHEMBL6336730 | 0.81 | ADRB3 (0.77) | ADRB3ADRB2HPGDADRB1 | |
| SCHEMBL6328720 | 0.79 | ADRB3 (0.51) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6337986 | 0.75 | ADRB3 (0.72) | ADRB3ADRB2ADRB1 | |
| SCHEMBL27575428 | 0.75 | ADRB3 (0.72) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885HPGD 2660/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885HPGD 2765/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | ADRB3 1/4885ADRB2 4/4885HPGD 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.